Standard management of sickle cell disease complications | Zendy

Miguel R. Abboud | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Standard management of sickle cell disease complications

Author(s) -

Miguel R. Abboud

Publication year - 2020

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2019.12.007

Subject(s) - medicine , disease , stroke (engine) , acute chest syndrome , pediatrics , intensive care medicine , mortality rate , survival rate , public health , sickle cell anemia , surgery , pathology , mechanical engineering , engineering

Sickle cell disease remains a major public health concern in sub-Saharan Africa, Europe, and the United States. The survival rate of children and adolescents has increased immensely in developed countries, whereas the survival rate for adults lagged behind. The increase in the pediatric survival rate is attributable to the institution of hydroxyurea treatment as well as stroke prevention strategies. In this review, we discuss the management of the sickle disease major complications such as pain, stroke, and acute chest syndrome with the most current hydroxyurea use and transfusion therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research